Sierra Oncology Granted US and EU Patents for Chk1 inhibitor SRA737

VANCOUVER, May 30, 2017 /PRNewswire/ –¬†Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today reported it has been issued a selection patent for its Chk1 inhibitor, SRA737, from the U.S. Patent and Trademark Office. The patent explicitly covers SRA737 and extends its protection out to 2033 in the U.S., before any patent term extensions.